Regulus Therapeutics (NASDAQ:RGLS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The firm currently has a $0.25 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 1.63% from the stock’s current price.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
RGLS has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Regulus Therapeutics in a research report on Tuesday, January 25th. StockNews.com assumed coverage on shares of Regulus Therapeutics in a research report on Friday. They set a “sell” rating on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Regulus Therapeutics in a research note on Monday.
Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last posted its earnings results on Thursday, March 10th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). During the same period in the previous year, the company earned ($0.03) EPS. On average, equities analysts anticipate that Regulus Therapeutics will post -0.22 EPS for the current year.
Several hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC grew its stake in Regulus Therapeutics by 38.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 111,000 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 31,000 shares in the last quarter. Morgan Stanley grew its stake in Regulus Therapeutics by 13.0% in the 3rd quarter. Morgan Stanley now owns 564,462 shares of the biopharmaceutical company’s stock valued at $390,000 after buying an additional 64,837 shares in the last quarter. Geode Capital Management LLC grew its stake in Regulus Therapeutics by 13.8% in the 3rd quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 81,551 shares in the last quarter. Asymmetry Capital Management L.P. grew its stake in Regulus Therapeutics by 94.9% in the 4th quarter. Asymmetry Capital Management L.P. now owns 2,731,044 shares of the biopharmaceutical company’s stock valued at $860,000 after buying an additional 1,329,553 shares in the last quarter. Finally, DAFNA Capital Management LLC purchased a new position in Regulus Therapeutics in the 4th quarter valued at approximately $1,750,000. Institutional investors own 47.06% of the company’s stock.
Regulus Therapeutics Company Profile (Get Rating)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.